Next earnings date: 11 Aug 2025
Citius Pharmaceuticals, Inc. – NASDAQ:CTXR
Citius Pharmaceuticals stock price today
$1.29
-2.39
-64.95%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Citius Pharmaceuticals stock price monthly change
+401.43%
month
Citius Pharmaceuticals stock price quarterly change
+401.43%
quarter
Citius Pharmaceuticals stock price yearly change
+366.30%
year
Citius Pharmaceuticals key metrics
Market Cap | 20.74M |
Enterprise value | N/A |
P/E | -6.95 |
EV/Sales | N/A |
EV/EBITDA | 1.32 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.24 |
Revenue | N/A |
EBITDA | -40.25M |
Income | -37.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCitius Pharmaceuticals stock price history
Citius Pharmaceuticals stock forecast
Citius Pharmaceuticals financial statements
| Mar 2023 | 0 | -10.52M | |
|---|---|---|---|
| Jun 2023 | 0 | -8.47M | |
| Sep 2023 | 0 | -9.94M | |
| Mar 2024 | 0 | -8.54M |
| Sep 2025 | 12.39M | 0 | |
|---|---|---|---|
| Oct 2025 | 12.39M | 0 | |
| Dec 2025 | 46.00M | 0 | |
| Mar 2026 | 48.00M | 0 |
Analysts Price target
Financials & Ratios estimates
| 2024-08-12 | -0.05 | -0.06 |
|---|
| Mar 2023 | 104240826 | 12.43M | 11.93% |
|---|---|---|---|
| Jun 2023 | 110404835 | 12.10M | 10.96% |
| Sep 2023 | 103611150 | 12.17M | 11.76% |
| Mar 2024 | 90711369 | 10.74M | 11.84% |
| Mar 2023 | -7.85M | 0 | 31.26K |
|---|---|---|---|
| Jun 2023 | -9.58M | 0 | 13.79M |
| Sep 2023 | -6.80M | 0 | -687 |
| Mar 2024 | -7.78M | 0 | 0 |
Citius Pharmaceuticals alternative data
| Aug 2023 | 21 |
|---|---|
| Sep 2023 | 21 |
| Oct 2023 | 21 |
| Nov 2023 | 21 |
| Dec 2023 | 21 |
| Jan 2024 | 21 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Citius Pharmaceuticals other data
3.00%
-6.75%
of CTXR is owned by hedge funds
36
-14
4.38M
-9.86M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2019 | 2588996 | 0 |
| Sep 2019 | 5586594 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 558,597 | $1.15 | $642,387 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Warrant to Purchase Common Stock | 558,597 | $1.15 | $642,387 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Warrant to Purchase Common Stock | 2,234,700 | $3.45 | $7,709,715 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 2,234,700 | $3.45 | $7,709,715 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 129,450 | $1.15 | $148,868 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Warrant to Purchase Common Stock | 129,450 | $1.15 | $148,868 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Warrant to Purchase Common Stock | 1,165,048 | $3.45 | $4,019,416 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 1,165,048 | $3.45 | $4,019,416 | ||
Purchase | MAZUR LEONARD L director, 10 perc.. | Common Stock | 3,137,255 | $3.45 | $10,823,530 | ||
Purchase | HOLUBIAK MYRON Z director, 10 perc.. | Common Stock | 784,314 | $1.15 | $901,961 |
-
What's the price of Citius Pharmaceuticals stock today?
One share of Citius Pharmaceuticals stock can currently be purchased for approximately $1.29.
-
When is Citius Pharmaceuticals's next earnings date?
Citius Pharmaceuticals, Inc. is estimated to report earnings on Monday, 11 Aug 2025.
-
Does Citius Pharmaceuticals pay dividends?
No, Citius Pharmaceuticals does not pay dividends.
-
How much money does Citius Pharmaceuticals make?
Citius Pharmaceuticals has a market capitalization of 20.74M. Citius Pharmaceuticals made a loss 39.43M US dollars in net income (profit) last year or -$0.06 on an earnings per share basis.
-
What is Citius Pharmaceuticals's stock symbol?
Citius Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CTXR".
-
What is Citius Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Citius Pharmaceuticals?
Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Citius Pharmaceuticals's key executives?
Citius Pharmaceuticals's management team includes the following people:
- Mr. Myron Z. Holubiak Pres, Chief Executive Officer & Director(age: 78, pay: $1,480,000)
- Mr. Leonard L. Mazur Executive Chairman & Sec.(age: 80, pay: $592,920)
- Dr. Myron S. Czuczman M.D. Executive Vice President & Chief Medical Officer(age: 66, pay: $549,670)
- Mr. Jaime Bartushak Chief Financial Officer & Chief Accounting Officer(age: 57, pay: $500,930)
-
How many employees does Citius Pharmaceuticals have?
As Jul 2024, Citius Pharmaceuticals employs 22 workers.
-
When Citius Pharmaceuticals went public?
Citius Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 2 Oct 2014.
-
What is Citius Pharmaceuticals's official website?
The official website for Citius Pharmaceuticals is citiuspharma.com.
-
Where are Citius Pharmaceuticals's headquarters?
Citius Pharmaceuticals is headquartered at 11 Commerce Drive, Cranford, NJ.
-
How can i contact Citius Pharmaceuticals?
Citius Pharmaceuticals's mailing address is 11 Commerce Drive, Cranford, NJ and company can be reached via phone at +90 89676677.
Citius Pharmaceuticals company profile:
Citius Pharmaceuticals, Inc.
citiuspharma.comExchange:
NASDAQ
Full time employees:
22
Industry:
Biotechnology
Sector:
Healthcare
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
11 Commerce Drive
Cranford, NJ 07016
Cranford, NJ 07016
CIK: 0001506251
ISIN: US17322U2078
CUSIP: 17322U207
